Novel arylcarbamate-N-acylhydrazones derivatives as promising BuChE inhibitors: Design, synthesis, molecular modeling and biological evaluation

• Published in: Bioorganic & medicinal chemistry 2021-02, Vol.32, p.115991, Article 115991
• Main Authors: Yamazaki, Diego A.S., Rozada, Andrew M.F., Baréa, Paula, Reis, Elaine C., Basso, Ernani A., Sarragiotto, Maria Helena, Seixas, Flávio A.V., Gauze, Gisele F.
• Format: Article
• Language: English
• Subjects: Butyrylcholinesterase inhibitors; Carbamates; Molecular modeling; N-acylhydrazones
• ISSN: 0968-0896; 1464-3391
• DOI: 10.1016/j.bmc.2020.115991

[Display omitted] •Design arylcarbamate-N-acylhydrazones derivatives were BuChE selective inhibitors.•The compounds were synthesized using low-cost and simple methodologies.•Compounds 10a-d are potent BuChE inhibitors, with IC50 values of 0.07–0.56 µM.•Best inhibitor 10c is non-competitive type of BuChE.•Docking studies confirmed important interactions of 10c with hBuChE active site. A novel series of arylcarbamate-N-acylhydrazones derivatives have been designed and synthesized as potential anti-cholinesterase agents. In vitro studies revealed that these compounds demonstrated selective for butyrylcholinesterase (BuChE) with potent inhibitory activity. The compounds 10a-d, 12b and 12d were the most potent BuChE inhibitors with IC50 values of 0.07–2.07 µM, highlighting the compound 10c (IC50 = 0.07 µM) which showed inhibitory activity 50 times greater than the reference drug donepezil (IC50 = 3.54 µM). The activity data indicates that the position of the carbamate group in the aromatic ring has a greater influence on the inhibitory activity of the derivatives. The enzyme kinetics studies indicate that the compound 10c has a non-competitive inhibition against BuChE with Ki value of 0.097 mM. Molecular modeling studies corroborated the in vitro inhibitory mode of interaction and show that compound 10c is stabilized into hBuChE by strong hydrogen bond interaction with Tyr128, π-π stacking interaction with Trp82 and CH⋯O interactions with His438, Gly121 and Glu197. Based on these data, compound10cwas identified as low-cost promising candidate for a drug prototype for AD treatment.